Search Results - "Gustavson, Stephanie"

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis by Bethel, M Angelyn, Patel, Rishi A, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B, Mentz, Robert J, Pagidipati, Neha J, Chan, Juliana C, Gustavson, Stephanie M, Iqbal, Nayyar, Maggioni, Aldo P, Öhman, Peter, Poulter, Neil R, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F, Holman, Rury R

“…Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular…”
Get full text

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL by Standl, Eberhard, Stevens, Susanna R, Lokhnygina, Yuliya, Bethel, M Angelyn, Buse, John B, Gustavson, Stephanie M, Maggioni, Aldo P, Mentz, Robert J, Hernandez, Adrian F, Holman, Rury R

“…We sought to confirm a bidirectional association between severe hypoglycemic events (SHEs) and cardiovascular (CV) event risk and to characterize individuals…”
Get full text

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes by Bethel, M. Angelyn, Stevens, Susanna R., Buse, John B., Choi, Jasmine, Gustavson, Stephanie M., Iqbal, Nayyar, Lokhnygina, Yuliya, Mentz, Robert J., Patel, Rishi A., Öhman, Peter, Schernthaner, Guntram, Lecube, Albert, Hernandez, Adrian F., Holman, Rury R.

“…BACKGROUND:EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2…”
Get full text

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial by Clegg, Lindsay E, Penland, Robert C, Bachina, Srinivas, Boulton, David W, Thuresson, Marcus, Heerspink, Hiddo J L, Gustavson, Stephanie, Sjöström, C David, Ruggles, James A, Hernandez, Adrian F, Buse, John B, Mentz, Robert J, Holman, Rury R

“…Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in…”
Get full text

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) by Bethel, M Angelyn, Patel, Rishi A, Thompson, Vivian P, Merrill, Peter, Reed, Shelby D, Li, Yanhong, Ahmadi, Sara, Katona, Brian G, Gustavson, Stephanie M, Ohman, Peter, Iqbal, Nayyar, Gagel, Robert F, Hernandez, Adrian F, Buse, John B, Holman, Rury R

“…Increases in serum calcitonin, a tumor marker for medullary thyroid carcinoma (MTC), have been associated with glucagon-like peptide 1 receptor agonist use in…”
Get full text

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease: Prespecified Analysis From EXSCEL by Mentz, Robert J, Thompson, Vivian P, Aguilar, David, Choi, Jasmine, Gustavson, Stephanie M, Iqbal, Nayyar, Kong, Alice P, Öhman, Peter, Sattar, Naveed, Scott, Russell S, Wong, Yee Weng, Holman, Rury R, Hernandez, Adrian F

Get full text

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial by Becker, Frauke, Dakin, Helen A., Reed, Shelby D., Li, Yanhong, Leal, José, Gustavson, Stephanie M., Wittbrodt, Eric, Hernandez, Adrian F., Gray, Alastair M., Holman, Rury R.

“…The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial assessed once-weekly exenatide (EQW) vs. placebo, added to usual care in 14,752 patients…”
Get full text

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) by Reed, Shelby D, Li, Yanhong, Dakin, Helen A, Becker, Frauke, Leal, Jose, Gustavson, Stephanie M, Kartman, Bernt, Wittbrodt, Eric, Mentz, Robert J, Pagidipati, Neha J, Bethel, M Angelyn, Gray, Alastair M, Holman, Rury R, Hernandez, Adrian F

“…To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or…”
Get full text

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial by Mentz, Robert J, Bethel, M Angelyn, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B, Chan, Juliana C, Felício, João S, Goodman, Shaun G, Choi, Jasmine, Gustavson, Stephanie M, Iqbal, Nayyar, Lopes, Renato D, Maggioni, Aldo P, Öhman, Peter, Pagidipati, Neha J, Poulter, Neil R, Ramachandran, Ambady, Reicher, Barry, Holman, Rury R, Hernandez, Adrian F

“…Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse…”
Get full text

Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment by Sharma, Raman, Litchfield, John, Bergman, Arthur, Atkinson, Karen, Kazierad, David, Gustavson, Stephanie M, Di, Li, Pfefferkorn, Jeffrey A, Kalgutkar, Amit S

“…A previous report from our laboratory disclosed the identification of PF-04991532…”
Get full text

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure by Tardif, Jean‐Claude, Rouleau, Jean, Chertow, Glenn M., Al‐Shurbaji, Ayman, Lisovskaja, Vera, Gustavson, Stephanie, Zhao, Yanli, Bouabdallaoui, Nadia, Desai, Akshay S., Chernyavskiy, Alexander, Evsina, Maria, Merkely, Béla, McMurray, John J.V., Pfeffer, Marc A.

“…Aims Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the…”
Get full text

Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects by Dai, Haiqinq, Gustavson, Stephanie M., Preston, Gregory M., Eskra, James D., Calle, Roberto, Hirshberg, Boaz

“…Aim:  Dipeptidyl peptidase‐IV (DPP‐IV) inhibitors represent a new promising therapeutic intervention for the treatment of type 2 diabetes mellitus. The aim of…”
Get full text

Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man by Gustavson, Stephanie M, Sandoval, Darleen A, Ertl, Andrew C, Bao, Shichun, Raj, Satish R, Davis, Stephen N

“…Antecedent increases of corticosteroids can blunt counterregulatory responses to subsequent stress. Our aim was to determine whether prior activation of type I…”
Get more information

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus by Gustavson, Stephanie M, Dai, Haiqing, Preston, Gregory M, Somayaji, Veena, Hirshberg, Boaz, Calle, Roberto A

“…Abstract A randomized, placebo-controlled study evaluated the effects multiple-doses (28 days) dipeptidyl peptidase-IV (DPP-IV) inhibitor PF-734200 on DPP-IV…”
Get full text

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs by Nishizawa, Makoto, Moore, Mary Courtney, Shiota, Masakazu, Gustavson, Stephanie M, Snead, Wanda L, Neal, Doss W, Cherrington, Alan D

“…Arteriovenous difference and tracer ([3-(3)H]glucose) techniques were used in 42-h-fasted conscious dogs to identify any insulin-like effects of intraportally…”
Get more information

Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog by Gustavson, Stephanie M, Chu, Chang An, Nishizawa, Makoto, Farmer, Ben, Neal, Doss, Yang, Ying, Donahue, E Patrick, Flakoll, Paul, Cherrington, Alan D

“…Epinephrine increases net hepatic glucose output (NHGO) mainly via increased gluconeogenesis, whereas glucagon increases NHGO mainly via increased…”
Get more information

Intraportal administration of neuropeptide Y and hepatic glucose metabolism by Nishizawa, Makoto, Shiota, Masakazu, Moore, Mary Courtney, Gustavson, Stephanie M, Neal, Doss W, Cherrington, Alan D

“…We examined whether intraportal delivery of neuropeptide Y (NPY) affects glucose metabolism in 42-h-fasted conscious dogs using arteriovenous difference…”
Get more information

Islet Auto‐Transplantation into an Omental or Splenic Site Results in a Normal Beta Cell but Abnormal Alpha Cell Response to Mild Non‐Insulin‐Induced Hypoglycemia by Gustavson, Stephanie M., Rajotte, Ray V., Hunkeler, David, Lakey, Jonathan R. T., Edgerton, Dale S., Neal, Doss W., Snead, Wanda L., Penaloza, Angelina R., Cherrington, Alan D.

“…The present studies were designed to determine if totally pancreatectomized dogs that underwent islet auto‐transplantation retained a functional pancreatic…”
Get full text

Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion by Gustavson, Stephanie M, Chu, Chang An, Nishizawa, Makoto, Farmer, Ben, Neal, Doss, Yang, Ying, Vaughan, Suzan, Donahue, E Patrick, Flakoll, Paul, Cherrington, Alan D

“…It was previously shown that glucagon and epinephrine have additive effects on both gluconeogenic and glycogenolytic flux. However, the changes in…”
Get more information

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes by Holman, Rury R, Bethel, M. Angelyn, Mentz, Robert J, Thompson, Vivian P, Lokhnygina, Yuliya, Buse, John B, Chan, Juliana C, Choi, Jasmine, Gustavson, Stephanie M, Iqbal, Nayyar, Maggioni, Aldo P, Marso, Steven P, Öhman, Peter, Pagidipati, Neha J, Poulter, Neil, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F

“…This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular…”
Get full text